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S U M M A R Y
Objectives: The treatment of tuberculosis (TB) remains a challenge owing to the high incidence of drug-
induced hepatotoxicity. The aim of this study was to examine the effect of two gene polymorphisms, one
in the CYP2B6 (rs3745274) gene and one in the CYP3A5 (rs776746) gene, on the development of
hepatotoxicity in patients treated with anti-TB drugs in a Brazilian Amazon population.
Methods: TB patients who were treated with anti-TB drugs were examined for hepatotoxicity, an
adverse effect that is characterized by liver damage. The genotype frequencies of the CYP2B6 and
CYP3A5 genes examined in this study were assessed using RT-PCR.
Results: Thirty-one of the 220 subjects (14.1%) included in this study developed drug-induced
hepatotoxicity. The result was signiﬁcant when the TT homozygous mutant of the CYP2B6 gene was
analyzed with additional key variables (p = 0.046; odds ratio (OR) 0.063, 95% conﬁdence interval (CI)
0.004–0.955), which may explain the hepatotoxicity results in this study. Using a univariate statistical
model to associate the CYP3A5 gene A6986G polymorphism with the examined drugs, the results did not
differ between samples from individuals with and without hepatotoxicity (p = 0.176; OR 0.562, 95% CI
0.255–1.238).
Conclusions: The G516T polymorphism in the CYP2B6 gene is a key predictor of the therapeutic response
to treatment in TB patients.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-
nc-sa/3.0/).
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Tuberculosis (TB) is a re-emerging global public health problem
despite the existence of national and international TB control
programs. Recent data from the World Health Organization (WHO)
show that approximately 8–10 million new cases arise annually,
with 2–3 million eventual deaths from the disease every year.1–3
In Brazil, the standard treatment for this disease is a
combination of three drugs, isoniazid (INH), rifampin (RMP),
and pyrazinamide (PZA); TB patients are treated for 6 months.4
Anti-TB drug use is related to a high risk for developing adverse
drug reactions (ADRs).5,6 The most serious adverse effect is
hepatotoxicity, which is characterized by various liver injuries* Corresponding author.
E-mail address: sidneysantos@ufpa.br (S. Santos).
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1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).and is associated with increased expenditure for treatment, as well
as high rates of morbidity and mortality.7,8 Various research
studies have suggested that the development of drug-induced
hepatotoxicity is related to a combination of RMP and INH. RMP
induces isoniazid hydrolase, increasing the production of acetyl
hydrazine (a metabolite of INH) when RMP is combined with INH
(especially in slow acetylators), which could explain the higher
toxicity of the combination.9–14 The primary genes involved in
metabolizing RMP and INH belong to the cytochrome P450 family,
and CYP2B6 and CYP3A5 are the most studied genes within this
pathway.12,15,16
In this study, we examined two single nucleotide polymor-
phisms (SNPs) involved in the response to anti-TB drugs in CYP2B6
(rs3745274) and CYP3A5 (rs776746) in a sample of 220 patients
with TB from a Brazilian Amazon population. The aim of this study
was to identify associations between the polymorphisms and the
risk of hepatotoxicity. Because the population studied is composedciety for Infectious Diseases. This is an open access article under the CC BY-NC-SA
Table 1
Demographic and clinical characteristics of cases with hepatotoxicity and controlsa
Characteristic Hepatotoxicity:
yes (n = 31)
Hepatotoxicity:
no (n = 189)
p-Value
Gender, female 14 (45) 98 (52) 0.562
Age, years 52.32  15.28 47.36  17.92 0.094
Smoker 16 (52) 39 (21) 0.001
Alcohol abuser 14 (47) 35 (19) 0.002
HIV 8 (26) 7 (4) <0.001
Use of other medicines 17 (55) 50 (27) 0.003
Present comorbidities 22 (71) 47 (25) <0.001
Slow acetylatorsb 11 (35) 55 (29) 0.020
African ancestry 0.27  0.12 0.25  0.12 0.461
European ancestry 0.39  0.11 0.41  0.13 0.548
Native American 0.34  0.11 0.33  0.11 0.651
Laboratory analyses
ALT, ml/ml,
pre-treatment
25.00  13.3 23.46  13.45 0.556
ALT, ml/ml, 30 days 49.93  15.85 22.52  11.79 <0.01
ALT, ml/ml, 60 days 82.7  17.3 22.7  2.0 <0.01
ALT, alanine aminotransferase.
a Results are given as the number (percentage) for categorical data, and as the
mean  standard deviation for quantitative data.
b Patients who are slow acetylators for the drug isoniazid.
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informative markers (AIMs) to estimate the individual inter-ethnic
admixture. This panel also acted as a genomic ancestry control for
the experimental and control samples to avoid spurious inter-
pretations from a population substructure.17
2. Methods
2.1. Study population
The sample consisted of 220 patients with pulmonary TB from
the Joa˜o de Barros Barreto University Hospital in the city of Bele´m,
the capital of the Amazonian state of Para´, Brazil. All had been
diagnosed with TB and treated with INH, RMP, and PZA for the
ﬁrst 2 months, followed by INH and RMP daily for 4 months.
This study was approved by the research ethics committee of
the hospital. The patients enrolled in the study provided written
informed consent. The following exclusion criteria were applied:
age <18 years, mental disability, chronic liver disease conﬁrmed by
clinical and laboratory data, anti-TB drug use prior to enrolment in
the study, and liver function test results before beginning
treatment that were greater than twice the normal limit.
Clinical and epidemiological data, including gender, age,
alcohol abuse, tobacco smoking, HIV, ethnicity, other diseases,
and concomitant use of other medications, were collected through
an interview using a standardized questionnaire and review of
each patient’s medical records.
Patients with hepatotoxicity induced by anti-TB drugs were
deﬁned in accordance with the international consensus criteria for
the timing and cause of drug-induced liver disease in this natural,
observation-based study. Hepatotoxicity was deﬁned as an
increase in serum alanine aminotransferase (ALT) greater than
three times the upper limit of normal levels after treatment.18 The
ALT level was estimated in the laboratory of the Hospital
Universita´rio Joa˜o de Barros Barreto by the enzymatic automated
method of optimized UV (IFCC);19 this was assessed prior to anti-
TB treatment and at 30 and 60 days following treatment onset, or
when the doctor suspected hepatotoxicity.
The patients were divided into two groups according to their
anti-TB drug response and pharmacological interactions assessed
during treatment. The groups were split based upon clinical
presentation: group I comprised patients who did not develop
drug-induced hepatotoxicity (189 subjects) and group II com-
prised patients with TB who developed drug-induced hepatotox-
icity (31 subjects).
2.2. Laboratory procedures
Genomic DNA was isolated from peripheral blood leukocytes
using standard procedures. Polymorphisms in the CYP2B6 gene
(G516T – rs3745274) and CYP3A5 gene (A6986G – rs776746) were
genotyped using TaqMan R SNP genotyping assays (Applied
Biosystems, Foster City, CA, USA). Estimates for the individual
inter-ethnic admixture were assessed using a panel of AIMs, as
described previously.17
2.3. Statistical analyses
Estimates for the individual inter-ethnic admixtures were assessed
as described previously.17 Additional statistical analyses were
performed using SPSS v.18 statistical software (SPSS Inc., Chicago,
IL, USA). Group comparisons of categorical variables were performed
using the Chi-square test, and the Student’s t-test was used to
analyze continuous variables. Multiple logistic regression analyses
were performed to estimate the odds ratio (OR) with 95% conﬁdence
interval (CI). For these analyses, the covariates gender, age, use ofmedicines other than INH, RMP, and PZA, tobacco smoking, alcohol
abuse, comorbidities, and ancestry were regarded as potential
confounders; these were analyzed carefully and modeled to avoid
multicollinearity, small cell frequencies, and excess independent
variables. A 5% signiﬁcance level was used for the analyses.
3. Results
Thirty-one of the 220 subjects (14.1%) included in the
study developed drug-induced hepatotoxicity. Table 1 shows the
demographic and clinical characteristics of the study patients.
The mean  standard deviation (SD) age of the total study population
was 49.8  16.6 years, and 112 patients (51.1%) were females.
Gender and age did not differ between the patients with and without
hepatotoxicity.
Tobacco smokers and alcohol abusers were more frequent
among patients with hepatotoxicity (p = 0.001 and p = 0.002,
respectively), and patients with hepatotoxicity had more comor-
bidities (p < 0.001). The data presented in Table 1 for slow
acetylators differ between the two groups analyzed (p = 0.020).
Fifteen (7%) of the 220 subjects had HIV/AIDS; there was a
signiﬁcant difference between the groups examined (p < 0.001).
The data collected showed that the African, European, and
Amerindian ancestry mean ratios were not signiﬁcantly different
between the two groups examined (p > 0.05). Figure 1 shows the
individual parental ethnic contribution of the case group (patients
with hepatotoxicity) and control group (patients without hepato-
toxicity) estimated through 48 AIMs.
As expected, the measured ALT at 30 and 60 days was
signiﬁcantly higher in cases with hepatotoxicity as compared to
those without this condition (p < 0.01). The ALT values before
treatment did not differ among the groups investigated.
Hardy–Weinberg equilibrium was evaluated by a simple count
of the genotypes obtained through the investigated markers. The
G156T polymorphism in the CYP2B6 gene was in Hardy–Weinberg
equilibrium (Chi-square = 3.467; p = 0.063), but the A6986G
polymorphism in the CYP3A5 gene was not in Hardy–Weinberg
equilibrium (Chi-square = 26.901; p > 0.05).
Table 2 presents the individual distribution by genotype,
stratiﬁed according to the presence or absence of hepatotoxicity.
We evaluated the effect of the G516T and A6986G polymorphisms
by multiple logistic regression analysis of the CYP2B6 and CYP3A5
genes, respectively, for the development of hepatotoxicity. The
Figure 1. Individual estimate of the inter-ethnic admixture between the groups with
and without hepatotoxicity. European, African, and Native American ancestries were
estimated by genotyping of the panel of 48 ancestry informative markers in the groups
of patients with hepatotoxicity (magenta) and without hepatotoxicity (yellow). The
admixture was estimated by comparison with subjects from the parental
populations: European (green), African (red), and Native American (blue).
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the investigated groups (p > 0.05).
Our results provide evidence that the 516 TT homozygous
genotype in the CYP2B6 gene presents a signiﬁcant protective
effect on the development of liver toxicity caused by drug
administration (p = 0.046; OR 0.063, 95% CI 0.004–0.955).
4. Discussion
A case–control study was performed to investigate the
pharmacogenetic association between anti-TB drugs (combination
of INH and RMP) and drug-induced hepatotoxicity. In this study,
we identiﬁed a 14.1% prevalence of hepatotoxicity among TB
patients treated with anti-TB medication.
Previous investigations have suggested that the development of
hepatotoxicity caused by the administration of anti-TB drugs is
associated with genetic variants (SNPs) in important genes
involved in the metabolic pathway of these drugs.20–24 CYP2B6
(G516T) and CYP3A5 (A6986G) have been examined widely inTable 2
Distribution of the frequencies of CYP2B6 and CYP3A5 variants in relation to
hepatotoxicity during anti-tuberculosis treatment
Gene/SNPs
and genotype
With
hepatotoxicity,
n (%)
Without
hepatotoxicity,
n (%)
Chi-square
association
exact test
p-Value OR (95% CI)
CYP2B6/516
TT 1 (3.2) 13 (7.0)
TG 18 (58.1) 86 (46.0)
GG 12 (38.7) 90 (47.6)
Total 31 189 0.046 0.063
(0.004–0.955)a
CYP3A5/6986
GG 0 0
GA 20 (64.5) 94 (49.7)
AA 11 (35.5) 95 (50.3)
Total 31 189 0.176 0.562
(0.255–1.238)a
SNP, single nucleotide polymorphism; OR, odds ratio; CI, conﬁdence interval.
a We used 516 TT homozygous of the CYP2B6 gene and 6986 AA homozygous of
the CYP3A5 gene for the risk analysis. For this calculation we used the multiple
logistic regression test. We used the presence of hepatotoxicity as a dependent
variable. The signiﬁcant independent variables from the univariate analysis used to
control for the model were the following: tobacco smoking, alcohol abuse,
comorbidity, use of other medicines, slow acetylators, and ethnicity.drug-induced hepatotoxicity studies;12,25–28 however, previous
research has not involved Brazilian admixed populations.
Because the Brazilian population is a product of miscegenation
(admixture) from three primary continental groups (European,
African, and Amerindian), we used a panel comprising 48 AIMs to
estimate the individual inter-ethnic admixture of the sample
subjects. We used the data collected to correct any spurious results
generated by the population substructure. The results showed that
the proportions of African, Amerindian, and European ancestry
were not signiﬁcantly different between the patients with liver
toxicity and those without liver toxicity. The method of genomic
control employed in this study has been used successfully in other
publications by this research group.24,29–33
The results from the multivariate statistical model used to
determine the association between the CYP3A5 gene A6986G
polymorphism and the drugs examined did not differ between the
patients with and without hepatotoxicity (p = 0.176; OR 0.562, 95%
CI 0.255–1.238). The CYP3A5 gene polymorphism results are
consistent with data published previously for other populations,
because no association was observed between the A6986G
polymorphism and drug-induced hepatotoxicity.12,34
The 516 TT homozygous mutant genotype for the CYP2B6 gene
was signiﬁcant (p = 0.046; OR 0.063, 95% CI 0.004–0.955) when
analyzed with other key variables, which may explain the
hepatotoxicity results. We found a signiﬁcant association between
the homozygous mutant genotype for the CYP2B6 gene and the
hepatotoxicity results, which demonstrates a protective factor for
non-development of this adverse effect.
Our results are consistent with those of several previous studies
that have found an association between the 516 TT polymorphism
and drug-induced hepatotoxicity.11,35 The data show the CYP2B6
gene to be a good marker for studying the response to anti-TB drug
treatment.
The observed hepatotoxicity in TB patients is a pharmacological
interaction between INH and RMP.11,13,36 Several studies have
reported that the co-administration of RMP and INH may increase
INH-induced toxicity by inducing CYP2B6 isoform expression
(especially in poor INH metabolizers), which is related to the
conversion of acetyl hydrazine (an INH metabolite) into reactive
and hepatotoxic compounds that may produce high drug-induced
hepatotoxicity in patients treated with such drugs.24,37–39
Our results are consistent with several studies in the literature
that have reported an increase in drug-induced hepatotoxicity
when patients are treated with both INH and RMP.12,39 Addition-
ally, our study showed that the CYP2B6 gene is a key predictor of
the anti-TB drug treatment response. Testing for the presence of
the 516 TT polymorphism in the CYP2B6 gene may aid in the
difﬁcult task of seeking a therapeutic balance for pharmacological
interactions between RMP–INH in the Brazilian Amazon popula-
tion with TB.
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